Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT03256136
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    Chemotherapy
  • Nivolumab — DRUG
    will allow the body's immune system to work against tumor cells
  • pemetrexed — DRUG
    Chemo therapy
  • Ipilimumab — DRUG
    will allow the body's immune system to work against tumor cells

Study Details

This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: * Nivolumab * Carboplatin * Pemetrexed * Ipilimumab

Key Dates

Start date
Nov 22, 2017
Status verified
Oct 2020
Primary completion
Aug 19, 2019
Completion
Aug 19, 2019

Study Design

Enrollment
9 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab Plus Ipilimumab EGFR
    Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
  • Experimental: Nivolumab Plus Ipilimumab ALK
    Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
  • Experimental: Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive
    Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
  • Experimental: Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive
    Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks

Primary Outcome Measure

Objective Response Rate (ORR), Presented in Numbers of Participants [ Time Frame: Up to approximately 2 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02115-
Dana Farber Cancer InstituteBostonMassachusetts02115-
Massachusetts general HospitalBostonMassachusetts02214-

Find similar trials in Boston, MA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Beth Israel Deaconess Medical Center· Boston, MADana Farber Cancer Institute· Boston, MAMassachusetts general Hospital· Boston, MA

Related Studies